Abingworth is an international bioscience investment firm that invests in seed stage projects, technology platforms, preclinical and clinical assets, and approved and marketed products. Its venture funds are focused on strategic areas of venture capital, clinical co-development, venture investments in public equities (VIPEs), and public markets. The firm supports companies at all stages of development, from start-ups to publicly traded companies, across all life sciences sectors, including biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics, and instrumentation.